Dr. Fryer’s Legacy; Zuranolone Starts Approval Process; Alzheimer’s Vax Fast-Tracked

The investigational schizophrenia treatment brilaroxazine demonstrated safety and tolerability in the ongoing phase III RECOVER study, Reviva Pharmaceuticals announced in an update. Topline data are expected in mid-2023.

How did Dr. John Fryer change the course of psychiatry after speaking at the American Psychiatric Association’s annual meeting in 1972? (NBC News)

Investigational COMP360 psilocybin therapy showed promise in people with anorexia nervosa and severe treatment-resistant depression in open-label exploratory studies, COMPASS Pathways announced.

A group of veterans filed a lawsuit against the U.S. Army for violating their rights by refusing to grant soldiers honorable discharges to qualify for federal benefits if they suffer from substance use disorders.

Sage Therapeutics and Biogen started a rolling submission new drug application to the FDA for its investigational drug zuranolone. The companies are expected to finish the application submission for major depressive disorder later in 2022 and another filing for postpartum depression in early 2023.

Mental health tech startup Cerebral allegedly pushed and overprescribed ADHD prescriptions to patients, according to a lawsuit filed earlier this week. (Forbes)

A rat study found that certain environmental cues can trigger alcohol cravings during withdrawal. (ScienceDaily)

The FDA granted fast track designation to UB-311, an anti-amyloid beta immunotherapeutic vaccine for the treatment of Alzheimer’s disease.

Prior to her recent death, singer Naomi Judd shared her struggles with severe depression. (CNN)